ArticleScientific reports2026
Sequential invitations to FOBT screening and colorectal cancer incidence.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effect of different sequences of invitations to Faecal Occult Blood Test (FOBT) screening regarding colorectal cancer (CRC) incidence has never been evaluated. In 2008-2012, all residents in Stockholm-Gotland, Sweden, born 1938-1954, were randomly assigned by birth year to different calendar years of invitation to guaiac-based FOBT (g) or Faecal Immunochemical Test (f) screening at 60-69 years (1-5 rounds), or not (0). Linkage was made to the national Cancer- and Cause of Death Registers on CRC diagnosis and mortality 1958-2020, and the Swedish Colorectal Cancer Register regarding stage. Follow-up started age 60 and CRC incidence, calculated per 100,000 person-years, was assessed during screening (age 60-69) and post screening (age 70-73). Stage I-II and III-IV was assessed post screening. 364,668 individuals were included. During screening, incidence rate ratio was significantly higher in sequences (0, g, g, g, g) (RR 1.25, 95% CI 1.09-1.43), (g, g, g, g, f) (RR 1.17, 95% CI 1.01-1.35), and (g, g, f, f, f) (RR 1.14, 95% CI 1.01-1.29). Post screening, the largest decrease was seen in sequences (g, g, g, g, f) and (g, g, g, f, f), RR 0.65, 95%, CI 0.47-0.90, and RR 0.53, 95% CI 0.30-0.94, respectively. There was an overall decreasing trend along sequences from (0, 0, 0, 0, g) to (g, g, f, f, f) post screening and both stages I-II and III-IV (p < 0.001). We could demonstrate a decreased CRC incidence post screening proportional to the number of invitations with implications for future modeling studies and risk-based screening strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.